Skip to main content
. 2020 Aug 14;10:1647. doi: 10.3389/fonc.2020.01647

FIGURE 4.

FIGURE 4

The predicted risk of grade ≥3 xerostomia at 9, 12, and 24 months after radiotherapy, using the Dtot dose variable. Note that not all categories are significantly different from each other with respect to the endpoint – the p-value only refers to the difference from the reference category (see Table 2 for p-values). No was reference for concomitant chemotherapy and Erbitux was not significantly different.